Newron Points ‘Future Value-Driver’ Evenamide At Drug-Resistant Schizophrenia

Following Phase II Promise

16 Feb 2023

• By Ayisha Sharma

The Italian firm’s VGSC-blocker has demonstrated long-term symptom improvement in a mid-stage trial in drug-resistant schizophrenia, expediting Phase III development plans that could help address a high unmet need.

One head split into two faces, one red and one blue, representing concept of schizophrenia — Schizophrenia Affects Around 24 Million People Worldwide • Source: Shutterstock

Newron Pharmaceuticals S.p.A.’s evenamide has shown signs of long-term safety and efficacy as an add-on therapy in a Phase II treatment-resistant schizophrenia (TRS) trial, sparking the advancement of pivotal development for the key value driver.

Evenamide blocks voltage-gated sodium channels (VGSCs), which is theorized to normalize glutamate release induced by aberrant sodium channel activity without...